First IPF Patient Enrolled in Phase 3 Study of Tyvaso

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who…

Where Do We Turn When Prescribed Therapies Aren’t Effective?

Managing symptoms is an ongoing challenge for chronically ill patients. Whether they’re caused by an exacerbation, disease progression, or environmental factors, it’s often difficult for patients to get quick relief, including from respiratory symptoms. Despite their name, rescue inhalers aren’t always effective in managing or improving pulmonary fibrosis…

Remembering My Mother, a Pillar on My Support Team

One of the most important blessings in life is having a strong support group. A support team may consist of family members, friends, or a community of people. My support team included three of the greatest people in my life: my husband, daughter, and mother. It is important…

Failed HIV Therapy May Combat COVID-19-induced PF

An experimental therapy that proved ineffective in treating HIV infections now has shown promising potential at preventing or limiting pulmonary fibrosis (PF) caused by SARS-CoV-2, the virus that causes COVID-19. That finding, from a mouse model of induced PF, was detailed in the study  “Targeting RUNX1…